Bos Sci nets win in latest DES patent battle with J&J
The U.S. District Court for the District of New Jersey has found all the asserted patents in a suit brought by Johnson & Johnson (J&J) to be invalid and entered judgment in favor of Boston Scientific.
As part of a 2008 suit, Johnson & Johnson alleged that Boston Scientific's Promus everolimus-eluting coronary stent system infringed two patents, U.S. Patent Nos. 5,516,781 and 5,563,146 (known as "the Morris patents"). The patents relate to the use of a drug on a drug-eluting stent.
"We are pleased with the court's finding that both of these Johnson & Johnson patents are invalid," said Tim Pratt, JD, executive vice president, chief administrative officer and general counsel for the Natick, Mass.-based Boston Scientific.
As part of a 2008 suit, Johnson & Johnson alleged that Boston Scientific's Promus everolimus-eluting coronary stent system infringed two patents, U.S. Patent Nos. 5,516,781 and 5,563,146 (known as "the Morris patents"). The patents relate to the use of a drug on a drug-eluting stent.
"We are pleased with the court's finding that both of these Johnson & Johnson patents are invalid," said Tim Pratt, JD, executive vice president, chief administrative officer and general counsel for the Natick, Mass.-based Boston Scientific.